Background: Dengzhan Shengmai Capsule (DZSMC) is a potential treatment for chronic heart failure (CHF). However, its specific benefits in the treatment of CHF remain unclear.
Methods: Related randomized controlled trials were searched in eight databases up to January 28, 2025, and included studies were determined according to the inclusion criteria. Subsequently, the basic characteristics and data from these studies were recorded using Excel 2010. Outcome-related data were subsequently imported into Revman 5.3 for meta-analysis.
Results: Fifteen randomized controlled trials with 1606 patients were included in this meta-analysis. The results showed that compared to conventional treatment group, DZSMC combination group significantly improved the clinical effective rate [RR = 1.21, 95% CI (1.16,1.26), < 0.00001], brain natriuretic peptide (BNP) [MD = -112.60, 95%CI (-212.23, -12.96), = 0.03], N-terminal pro-B-type natriuretic peptide (NT-proBNP) [MD = -88.27, 95%CI (-108.11, -68.42), < 0.00001], left ventricular ejection fraction (LVEF) [MD = 6.42, 95% CI (5.57, 7.27), < 0.00001], left ventricular end-diastolic diameter (LVEDD) [MD = -5.72, 95% CI (-7.56, -3.87), < 0.00001], left ventricular end-systolic diameter (LVESD) [MD = -5.33, 95% CI (-7.41, -3.26), < 0.00001], left ventricular end-systolic volume (LVESV) [MD = -20.71, 95% CI (-34.59, -6.82), = 0.003], and 6 min walk test [MD = 51.90, 95%CI (19.08, 84.72), = 0.002], while adverse events had no significant difference [RR = 0.70, 95%CI (0.42, 1.17), = 0.17]. Funnel plots indicated no publication bias for BNP, NT-proBNP, LVEF, and LVESD, while potential bias was observed for other outcomes.
Conclusion: DZSMC effectively improves clinical symptoms, cardiac function, and ventricular remodeling in CHF patients, with good safety, making it a potential adjuvant therapy for CHF. However, further research is needed to explore the long-term safety of DZSMC in order to enrich clinical evidence.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024507368, PROSPERO [CRD42024507368].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885271 | PMC |
| http://dx.doi.org/10.3389/fcvm.2025.1385061 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of Dengzhan Shengmai capsule in the treatment of chronic heart failure: a systematic review and meta-analysis.
Front Cardiovasc Med
February 2025
Department of Cardiovascular Medicine, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.
Background: Dengzhan Shengmai Capsule (DZSMC) is a potential treatment for chronic heart failure (CHF). However, its specific benefits in the treatment of CHF remain unclear.
Methods: Related randomized controlled trials were searched in eight databases up to January 28, 2025, and included studies were determined according to the inclusion criteria.
Dengzhan Shengmai capsule ameliorates cognitive impairment via inhibiting ER stress in APP/PS1 mice.
J Ethnopharmacol
February 2025
Department of Neurology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China; Department of Neurology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China. Electronic address:
Ethnopharmacological Relevance: Alzheimer's disease (AD) is a common type of neurodegenerative disease with the β-amyloid plaques (Aβ) deposition. Previously, Dengzhan Shengmai capsule (DZSM) has been shown to reduce the pathology associated with AD, but the underlying mechanism is unclear.
Aim Of Study: This study investigated the potential mechanisms of DZSM against AD.
Corrigendum to "Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca/CaMKII pathway" [J. Pharm. Anal. 14 (2024) 435-438].
J Pharm Anal
June 2024
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
[This corrects the article DOI: 10.1016/j.jpha.
View Article and Find Full Text PDFInvestigation of the efficacy of Dengzhan Shengmai capsule against heart failure with preserved ejection fraction.
J Ethnopharmacol
October 2024
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, 100700, China. Electronic address:
Ethnopharmacological Relevance: Heart failure with preserved ejection fraction (HFpEF) has emerged as a condition with high incidence and mortality rates in recent years. Dengzhan Shengmai capsule (DZSMC) is a Chinese patent medicine based on the classic recipe "Shengmai powder". The relevant Chinese medicine ratio of Erigeron breviscapus (Vaniot) Hand.
View Article and Find Full Text PDFAltered synaptic currents, mitophagy, mitochondrial dynamics in Alzheimer's disease models and therapeutic potential of Dengzhan Shengmai capsules intervention.
J Pharm Anal
March 2024
State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, 100875, China.
Emerging research suggests a potential association of progression of Alzheimer's disease (AD) with alterations in synaptic currents and mitochondrial dynamics. However, the specific associations between these pathological changes remain unclear. In this study, we utilized Aβ-induced AD rats and primary neural cells as and models.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!